Advances in MRSA drug discovery: where are we and where do we need to be? - Wikidata - thesis-toulmin - TriplyDB

Advances in MRSA drug discovery: where are we and where do we need to be?

Advances in MRSA drug discovery: where are we and where do we need to be?

http://www.wikidata.org/entity/Q37112508

about

Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps Pterostilbene, a Methoxylated Resveratrol Derivative, Efficiently Eradicates Planktonic, Biofilm, and Intracellular MRSA by Topical Application.Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.Naphtho[1,2-b]furan-4,5-dione is a potent anti-MRSA agent against planktonic, biofilm and intracellular bacteria.A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.Structural insights of lincosamides targeting the ribosome of Staphylococcus aureus.Proteases and protease inhibitors in infectious diseases.Zunyimycins B and C, New Chloroanthrabenzoxocinones Antibiotics against Methicillin-Resistant Staphylococcus aureus and Enterococci from Streptomyces sp. FJS31-2.Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.Strategies to Encapsulate the Bacteriophage phiIPLA-RODI

P2860

Q28821040-E6F30DD7-D2EE-4FDD-B7CE-6E0E9286C995 Q33659230-BF74F9A1-F01B-47B5-B94A-C7B3C485FC39 Q33790112-E33C9664-9FFD-44F1-9C92-3823A924CC03 Q34497915-13E36A10-CE64-47D5-9293-1F1014519D51 Q38643859-8CACF48D-1529-436E-AB7B-02A7CE574C43 Q41872353-3F666599-92F6-4592-95AA-ADF45C2C22B5 Q42140527-083DE241-7D4E-486D-BE33-0CAB0C2D2C69 Q47576680-2A018F96-252F-475F-BBA7-8A411260BB8C Q53499967-FF12C6AA-907C-4C6A-9AB1-8CA2664AEE77 Q53685683-72EB6C07-5074-45C4-B7AF-4EFCC679C25E Q58742505-F841F0E6-FB65-41FB-9F4F-67D9E944E644

P2860

Advances in MRSA drug discovery: where are we and where do we need to be?

http://www.wikidata.org/entity/Q37112508

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Advances in MRSA drug discovery: where are we and where do we need to be?

@en

Advances in MRSA drug discovery: where are we and where do we need to be?

@nl

type

label

Advances in MRSA drug discovery: where are we and where do we need to be?

@en

Advances in MRSA drug discovery: where are we and where do we need to be?

@nl

prefLabel

Advances in MRSA drug discovery: where are we and where do we need to be?

@en

Advances in MRSA drug discovery: where are we and where do we need to be?

@nl

P1433

Q37112508-659CA240-E1D5-4C06-AA55-1FF56DF895F8

P1476

Q37112508-619B82F5-B622-4961-80E8-EE5B07B022F2

P2093

Q37112508-0451F5D0-4D4F-4EE3-9797-C490EE0B0B65

Q37112508-211A0B5C-E31F-4012-8619-B36E686DD1DC

Q37112508-34DD03CE-C44E-42D9-A42A-CD1A49DAEE22

P2860

Q37112508-018D8B38-7584-4BCF-821D-AAA668BD52BB

Q37112508-034294D0-817B-497F-9ABA-5048CA1DB738

Q37112508-076EA5D9-35A3-4963-B14F-19715BC4E3EE

Q37112508-07B482C9-7185-46A5-8564-6C7FD698A8E2

Q37112508-07E586EE-20AD-49EC-867F-33BE15A4BFF7

Q37112508-0BF15C3F-02C5-42C5-8E64-B7C9B8389C97

Q37112508-0C3A08C6-ECAA-4EEC-933E-F3520CE96122

Q37112508-0E471FE2-D599-4248-8CB2-2D3C7EEF5094

Q37112508-18067BA9-B9EC-4B52-9F89-E37E7DC2B0BE

Q37112508-183FBA0F-A06C-4C6D-BD34-845864E244B8

P304

Q37112508-8FEC2279-8D2B-4B81-9F71-303FEF57AA4E

P31

Q37112508-0D7B3F62-5205-4FFF-AD15-6714A4D91F98

P356

Q37112508-AF934423-4DC7-4458-9753-A46C218312EA

P407

Q37112508-685DDE5D-C526-45AD-B0D7-6D13F8C14B9F

P433

Q37112508-D1980B05-BD4F-4C84-94C1-65E1139FF151

P478

Q37112508-56B6185B-F80B-4FB2-9AD9-26B294442756

P577

Q37112508-8D99A332-9421-4E3D-A49C-C3927C75F9EA

P5875

Q37112508-BADD9648-DE09-4F62-9132-AB8D205ADB03

P698

Q37112508-6A7BD785-83C2-439A-89A4-45A1ED55411A

P932

Q37112508-F1D38F33-6BAB-41F9-B48F-3AE317AB508C

P356

17460441.2013.807246

P1433

Expert Opinion on Drug Discovery

P1476

Advances in MRSA drug discovery: where are we and where do we need to be?

@en

P2093

Katsuhiko Mitachi

http://www.w3.org/2001/XMLSchema#string

Michio Kurosu

http://www.w3.org/2001/XMLSchema#string

Shajila Siricilla

http://www.w3.org/2001/XMLSchema#string

P2860

Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials

Phage Therapy in Clinical Practice: Treatment of Human Infections

Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid

MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain.

Discovery of FabH/FabF inhibitors from natural products.

Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing

R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance

In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens

Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae

P304

1095-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17460441.2013.807246

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

247154434

http://www.w3.org/2001/XMLSchema#string

P698

23829425

http://www.w3.org/2001/XMLSchema#string

P932

3750092

http://www.w3.org/2001/XMLSchema#string